PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25405174-2	2014	Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat.	riociguat	112-121	sarcoglycan beta	Homo sapiens	20-23	
25405174-2	2014	Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat.	riociguat	112-121	sarcoglycan beta	Homo sapiens	96-99	
34600441-2	2021	The first in class sGC stimulator riociguat was approved for pulmonary hypertension in 2013 and vericiguat very recently for heart failure.	riociguat	34-43	sarcoglycan beta	Homo sapiens	19-22	
29738821-5	2018	In 2013, the first sGC stimulator, riociguat, was approved for the treatment of PAH and chronic thromboembolic pulmonary hypertension (CTEPH).	riociguat	35-44	sarcoglycan beta	Homo sapiens	19-22